Dose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring

Similar documents
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?

Linee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona

Metastatic renal cancer (mrcc): Evidence-based treatment

Evidenze cliniche nel trattamento del RCC

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?

David N. Robinson, MD

Treatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria

Timing of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital

Second - Line Debate: Axitinib

Toxicity as a Biomarker

Cytoreductive Nephrectomy

Sequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC

Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents

Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better?

Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy

Fifteenth International Kidney Cancer Symposium

pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma

Medical Management of Renal Cell Carcinoma

Metastatic Renal Cancer Medical Treatment

Clinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.

Click to edit Master /tle style. Cardiovascular Toxicity in Renal Cell Carcinoma Pa/ents

Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce

UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA

Emerging Biomarkers of VEGF and mtor Inhibitors in 2015

Management of High Risk Renal Cell Carcinoma

Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea

Axitinib in renal cell carcinoma: now what do we do?

A Review in the Treatment Options for Renal Cell Cancer

Targeted and immunotherapy in RCC

Case(s): How to Deal with Mixed Response Giuseppe Procopio

What can we expect from running phase III trials: will all of them alter the current treatment algorithm?

Developping the next generation of studies in RCC

The Therapeutic Landscape in Advanced Renal Cell Carcinoma

Renal Cell Carcinoma: Systemic Therapy Progress and Promise

Tratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.

Renal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland

New strategies and future of target therapy in advanced kidney cancer

How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy

Complete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy

I Kid(ney) You Not: Updates on Renal Cell Carcinoma

CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT

Sequential Therapy in Renal Cell Carcinoma*

La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD

Atezolizumab Adjuvant Study: Medical Oncologist Perspective. Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center

Renal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy

Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?

Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis

Innovaciones en el tratamiento del ca ncer renal. Enrique Grande

Integration of Surgery And Systemic Therapy In The Treatment of

Why was HOPE 205 a Positive After Years of Negative Studies?

Renal Cell Carcinoma

Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute

CLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12

Cover Page. The handle holds various files of this Leiden University dissertation.

Kidney Cancer Session

Management del paziente dializzato Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena

ASCO 2012 Genitourinary tumors

Integrating novel therapy in advanced renal cell carcinoma

Drug-drug interactions with oncolytics (in particular PPIs and TKIs)

Reference No: Author(s) Approval date: June Committee. Operational Date: July Review:

NEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden

1 Introduction. Sebastiano Buti 1 Maddalena Donini. Francesco Leonardi 1 Rodolfo Passalacqua

Targeted Therapy in Advanced Renal Cell Carcinoma

ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients

The Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations

pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013

Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt

Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle

Prognostic Factors for mrcc: Relevance in Clinical Practice

Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy

Renal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation

Positioning Antiangiogenesis Drugs and Other Agents in Renal Cell Cancer Treatment

A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care

REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO

Checkpointinhibitoren in der Uro-Onkologie. Carsten Grüllich

Renal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto)

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

When to Treat Beyond Progression with Systemic Therapies? Manuela Schmidinger Medical University of Vienna, Austria

Treatment Options in RCC: Past, Present and Future. Pr Stéphane Oudard, MD, PhD Georges Pompidou Hospital Paris, France

The Really Important Questions Current Immunotherapy Trials are Not Answering

Sustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

Angiogenesis Targeted Therapies in Renal Cell Carcinoma

Antiangiogenics are effective treatments in NETs

ASCO 2011 Genitourinary Cancer

The Current Champion: Angiogenesis inhibitors

Angiogenesis and tumor growth

Cover Page. The handle holds various files of this Leiden University dissertation.

European consortium study on the availability of anti-neoplastic medicines

Introduction. pissn , eissn Cancer Res Treat. 2014;46(4):

Immunotherapy for the Treatment of Kidney and Bladder Cancer

TDM of Targeted Therapies in Oncology: where do we stand? Dr. Joseph Ciccolini SMARTc - Pharmacokinetics Unit AMU/APHM Inserm U1068 CRCM

Cabozantinib (Cometriq )

Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?

pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016

Technology appraisal guidance Published: 21 March 2018 nice.org.uk/guidance/ta512

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies

Camillo Porta S.C. di Oncologia Medica Università degli Studi di Pavia & I.R.C.C.S. Fondazione Policlinico San Matteo di Pavia

Transcription:

Dose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring Alison Zhang 1, Peter Fox 1, Sally Coulter 4, Val Gebski 5, Bavanthi Balakrishnar 1, Christopher Liddle 4, Howard Gurney 1,6 1 Westmead Hospital, Sydney, Australia 4 Westmead Millennium Institute, Sydney, Australia 5 NHMRC Clinical Trials Centre, Sydney, Australia 6 Faculty of Medicine and Health Sciences, Macquarie University

ESMO/EAU treatment algorithm for mrcc therapy 1,2 Setting Agent Treatmentnaїve* Good or intermediate risk Sunitinib Bevacizumab + IFN-α Pazopanib Poor risk Temsirolimus Previously treated Prior cytokine Prior VEGFR-TKI Pazopanib Sorafenib Axitinib Everolimus Axitinib Prior mtor inhibitor No recommendation 1. Escudier B, et al. Ann Oncol 2012;23(Suppl7):vii65-vii71. 2. Ljungberg B, et al. Eur Urol 2010;58:398-406. *Guidelines for clear cell mrcc

First line Sunitinib in mrcc Registration study Pooled 6 studies Expanded access Comparz N 750 1059 4564 494 Poor risk 6 4 9 9 No Nephrectomy 19 21 11 16 Age 62 60 62 ECOG 2 to 4 0 2 14? Non clear cell 0 3 13 0 Median PFS mths 11 9.7 10.9 9.5 Median OS mths 26.4 23.4 18.4 29.3 Motzer et al NEJM 2013; 369 (8) 772; Motzer et al Br J Cancer (2013) 108, 2470; Gore et al. Lancet Oncol 2009; 10: 757 63; Motzer, R. J. et al. J Clin Oncol; 27:3584-3590 2009

Dose reductions common Recommended dose of Sunitinib 50mg daily for 28 days then 14 day break Dose reductions in > 1/3 patients Expanded Access study (N = 4371 with dose info) 50 mg 56% 37.5 mg 33% 25 mg 13% 12.5 mg <1% } 46% below recommended dose Motzer et al. J Clin Oncol 30:1371-1377 2012; Gore et al. Lancet Oncol 2009; 10: 757 63

Dose reduction vs no dose reduction of sunitinib Khosravan et al ASCO GU 2012 Abst 363 Higher PFS in dose reduction patients

Dose individualization of sunitinib Bjarnason GA et al. Urol Oncol. 2014 32(4):480-7 Progression free survival 172 pts. Starting dose 50mg/d 28/14 Dose and schedule modified to keep Grade toxicity < 2

Rini BI, et al. J Natl Cancer Inst 2011;103:763 773; Michaelson MD, et al. ASCO GU, Orlando, 2011 Donskov F, et al. ECCO-ESMO, 2011; Davis MP, et al. ECCO-ESMO, 2011 Sunitinib Toxicity vs anticancer effect Hypertension Neutropenia Hand-foot syndrome Asthenia, fatique

TDM and Sunitinib disposition Metabolised by CYP3A4 to N-desethylsunitinib (Ndes) equipotent 30-50% of sunitinib level Half life Sunitinib ~50hr (SS ~ 10 days) Ndes ~100 hrs (SS ~ 20 days) Substantial Inter-patient variability ~10x Faivre et al, JCO, 2006

Exposure and anti-cancer effect High sunitinib AUC correlates with improved OS in mrcc and GIST AUC correlates with toxicity (HTN, neutropenia, fatigue) Measuring AUC in clinical setting is impractical Houk et al, Cancer Chemother Pharmacol, 2010

Trough Level Target Tumour xenograft sunitinib inhibits TKI phosphorylation at 50-100 ng/ml Houk metaanalysis high AUC = Su Trough level 35 ng/ml Su + Ndes ~ 50ng/mL? Target TTL = 50ng/mL Mendel, D. B. et al Clin. Cancer Res. 9, 327 337 (2003); Faivre et al. J Clin Oncol 24:25-35. 2006; Houk et al. Cancer Chemother Pharmacol. Dec 2009 ; de Wit et al Drug Discovery Today 2015

Background Trough level acquisition relatively simple BUT Routine use requires: 1. Demonstration that Intrapatient variation is LOW 2. Correlation of trough level with anticancer effect (PFS, OS)

CRESTO study Metastatic renal cell cancer Sunitinib 50mg/d (or 37.5mg) 28/14 or 14/7 schedule Trough sample for sunitinib + Ndes Toxicity-adjusted dose Optimum dose Treat until resistance Time-on-Treatment Could be on sunitinib before study entry

CRESTO study in mrcc Toxicity-adjusted dosing regimen Dose of sunitinib adjusted to ensure G1 or 2 toxicity for >10 days for each 42 day cycle 6 weekly review No or minimal toxicity Grade 1 or 2 for >10 days per 42d Grade 3 for >10d or any Grade 4 INCREASE dose by 12.5/d NO change in dose DECREASE dose by 12.5mg/d Optimum dose Gurney. J Clin Oncol. 1996 Sep;14(9):2590-611

Methods Bloods for Trough level collected every 6 weeks 24 hr (+/- 2hr) after sunitinib dose 28/14 schedule On day 27, 28 or 29 14/7 schedule On day 13, 14 or 15 Plasma concentrations of Sunitinib (Su) and N- desethyl Sunitinib (Ndes) liquid chromatography/mass spectrometry Total trough level = Su + Ndes NOT used for dose adjustment

Questions 1. Is toxicity-adjusted dosing (TAD) feasible for sunitinib in mrcc? 1. Does it allow does increase as well as dose reduction? 2. If Individualized dose is achieved by TAD 1. Will interpatient variation in sunitinib level be reduced? 2. Are sunitinib levels stable over time? (TDM) 3. Do more patients have a potentially effective sunitinib level compared to standard dose schedule? (50ng/mL) 4. Assessment of Time-on-Treatment as surrogate for PFS

Results 45 patients accrued at Westmead Hospital June 2012 to March 2014 283 Sunitinib and NDES samples assayed Number samples per patient Median number = 5 Range 1 to 18 Sampling period Median = 30 weeks Range 6 to 108 weeks

Patient characteristics N=45 Patient characteristics %. of patients Mean (range) Age (years) 62 (36-78) Male 80 Female 20 ECOG performance status 0 33 1 58 2 5 3, 4 5 Weight (kg) 83 (51-138) Histology Clear cell 90 Non-clear cell 10 Heng risk score Favourable risk 38 Intermediate risk 47 Poor risk 15 Radical/partial nephrectomy 88 Previous therapy 13

Sunitinib levels according to schedule Schedule 14/7 28/14 Dose 50mg (13.0) 37.5mg (10.1) Sunitinib level NDES TTL ng/ml (SD) 42.3 (19.0) 32.0 (19.4) 23.3 (16.8) 18.4 (11.0) 65.5 (30.1) 58.0 (26.3) p= 0.005 0.014 0.007 0.003 Longer schedule had significantly lower Sunitinib dose and Su, NDES and TTL

Dose variations Baseline Optimal dose Dose N (%) % 87.5 0 0 75 0 Dose Change 7% above 2 (5%) recommended 8 (20%) 62.5 0 1 (2%) 50 30 (68%) 23 (58%) 22 (50%) 7 (18%) 37.5 9 (21%) 43% below 12 (27%) 2 (5%) recommended 25 5 (11%) 8 (18%) 12.5 1 (2%) 0 Dose range in adjustment period = 12.5 to 87.5mg/d

Summary 1 Is toxicity-adjusted dosing (TAD) feasible for sunitinib in mrcc? TAD is feasible At least 7% can have a long term dose increase with tolerable toxicity 3-fold range in dose (25 to 75mg/d)

TTL vs dose Dose Baseline Median ng/ml (range) Optimum dose 87.5 -- - 75 -- 68.6 (33-123) 62.5 -- p= NS 79.5 50 78.4 (21-158) 37.5 56.7 (24-122) 25 55.9 (35-98) 71.3 (15 190) p<0.001 56.7 (19-127) p= NS 63.0 (21-97) 12.5 28.6 - Intermediate dose required? No dose escalation in absence of toxicity?

TTL before and after dose adjustment 160 140 120 Md TTL ng/ml* 100 80 92.6 60 40 50.4 64.6 p = 0.01 p = 0.006 20 0 Underdosed Optimum Overrdosed 0 1 2 3 4 Dose increased Dose reduced *Each point is median of multiple samples per patient

TTL and variation at Optimum dose Median TTL = 64.6ng/mL Mean TTL = 71.4ng/mL 38/45 (84.4%) had mean TTL >50ng/mL Inter-patient coefficient of variance = 33%

Median TTL interpatient variation TTL 180 160 140 120 100 TTL 80 ng/ml 60 75.8 67.4 70.7 40 20 0 Initial Dose Optimum Dose Clearsun study 0 1 2 3 CV 43% 33% 37%

Summary 2 Will inter-patient variation in sunitinib level be reduced with TAD? Maybe Interpatient variation in TTL is reduced but variation remains substantial

Low intra-patient variability at 250 Optimum dose 200 Suninitib + Ndes (ng/ml) 150 100 50 0 16 12 2 18 3 24 4 30 5 36 6 42 7 48 8 54 9 60 10 66 11 72 Weeks No accumulation of Su or Ndes across dosing cycles

Intra-patient variability Using TAD-strategy Mean intra-patient variation in TTL 21% 98% of TTL for all pts across measurement were within 2 SD of predicted TTL (standardised residuals) This indicates low intra-patient variability even in early trough levels

Summary 3 Are sunitinib levels stable over time on stable dose? Yes No significant intrapatient variation in TTL over repeated measures for up to 66 weeks

Time on treatment vs dose Optimal dose Mean Time on treatment p= 25mg 29.8m 37.5mg 33.8m ns 50mg 22.3m 0.08 >50mg 14.7m ns No correlation between dose and time on treatment Underdosed patients - anticancer effect not compromised

Time on treatment using TAD Median TTF: 25.0 months (95% CI 12-39m: Range 2.9-91+m) Mean TTF: 33.8 months Registration study Pooled 6 studies Expanded access Comparz This study N 750 1059 4564 494 44 Poor risk 6 4 9 9 15 No Nephrectomy 19 21 11 16 12 Age 62 60 62 62 ECOG 2 to 4 0 2 14? 10 Non clear cell 0 3 13 0 10 Median PFS 11 9.7 10.9 9.5 25.0* Median OS 26.4 23.4 18.4 29.3 - * TFF not PFS

Time on treatment vs < or > 50ng/mL TTL Mean TTL 77ng/mL 15% of patients Mean TTL 37ng/mL

Summary 4 Do more patients on TAD have a potentially effective sunitinib level compared to standard dose schedule? ~85% had TTL over 50ng/mL on Optimum dose TTF of 25 months - comparable to other series

Conclusions 1 - TAD Toxicity adjusted dose (TAD) is feasible and allows safe escalation and dose decrease with 3-fold dose range (25-75mg/d) TAD associated with favourable Time-on- Treatment (median 25mnths) Even low doses (associated with toxicity) have appropriate TTL (37.5mg cohort?underdosed) long Time-on-Treatment

Conclusions 2 potential for TDM Sunitinib levels do not vary significantly in patients on stable dose Single or limited blood sampling of trough levels may adequately define drug exposure TAD alone does not prevent low TTL 15% <50ng/mL Substantial inter-patient variation remains? some pts underdosed at 37.5mg/d? role for TDM for fine-tuning Definitive studies are required to determine whether sunitinib trough level correlate with anti-cancer effect

Planned phase 2 study First-line, Clear cell RCC Sunitinib 50mg/d 14/7 schedule 1 or 2 Trough samples to fine-tune dose TTL >50ng/mL Toxicity-adjusted dose Optimum dose Progression-free survival First-line Clear cell carcinoma N= 80 End-point is PFS >12 months?phase 3 study